Chance it happens
60%Belief the predicted event happens at all — every “yes / by-a-date” outcome added together. “Other” is tracked as its own third slice.
Outcomes
Resolution criteria
The indication of NewLimit's first registered study. Resolution horizon: 2028-12-31. Source: ClinicalTrials.gov.
Evidence & context
Trials, publications and reports our research found on this prognosis. Each links to the original source.
This is a NewLimit company blog post summarizing 2025 progress. It states the company began developing its first medicines in 2025 and built its first preclinical candidate, which is relevant because it indicates NewLimit was still at a preclinical stage and had not yet registered a clinical study, though it does not identify any specific future indication.
This is an official NewLimit blog post announcing a Series C and stating the company plans to bring its first aging reprogramming medicine to human clinical trials next year. It is relevant because it speaks directly to the timing and existence of NewLimit's first human study, though it does not specify the clinical indication.
This is a June 7, 2026 news article about NewLimit's financing and stated plan to start human trials the following year. It bears on the prognosis because it highlights the company's lead prototype as reversing cell age in old human liver cells, which weakly suggests a liver-related initial indication, though it does not name a clinical indication or registered study.